Neurocrine Biosciences, Inc.
NBIX Healthcare Drug Manufacturers Specialty & Generic
Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024. In the quarter to June 2026, revenue grew 39.5%, EPS grew 31.2% and free cash flow grew 43.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five.
Follow NBIX
A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Net Income |
705.50 | 668.60 | 478.60 | 428.00 |
+8 more TTM periods Free account |
Depreciation & Amortization |
37.60 | 17.10 | 17.40 | 3.50 | |
Non Cash Items (Other) |
304.60 | 286.10 | 414.80 | 358.20 | |
Accounts Receivable Change |
(259.60) | (255.00) | (210.50) | (246.90) | |
Change in inventories |
(17.90) | (9.30) | (15.30) | (23.50) | |
Change in payables and accrued liability |
125.30 | 148.90 | 160.20 | 161.00 | |
Income tax paid |
25.60 | 85.60 | (18.80) | 0.80 | |
Change in other assets and liabilities |
(22.50) | (78.30) | (44.40) | (45.10) | |
Other operating activities |
0.00 | — | 0.70 | 0.80 | |
Operating Cash Flow |
898.10 | 863.70 | 782.70 | 636.80 | |
Capital expenditures |
(27.70) | (32.40) | (34.00) | (43.70) | |
Short Term Investments Change (Net) |
(1,588.40) | (1,905.00) | (1,319.80) | (1,308.60) | |
Long-Term Investments Change (Net) |
3,616.90 | — | 1,387.50 | 1,370.60 | |
Investing cash flow |
(891.20) | (784.80) | (264.40) | (279.80) | |
Equity Repurchase (Common, Net) |
125.30 | 49.20 | (38.30) | (365.60) | |
Other financial activities |
43.60 | 88.50 | — | — | |
Financing cash flow |
60.20 | (6.50) | (38.30) | (365.60) | |
Change in Cash |
66.90 | 72.40 | 480.00 | (8.90) | |
Beginning Cash |
721.00 | 721.00 | 241.00 | 241.00 | |
Ending Cash |
787.90 | 793.40 | 721.00 | 232.10 | |
Stock Based Compensation |
234.50 | 222.30 | 217.90 | 225.70 | |
Dividends Paid (Common) |
0.00 | 0.00 | 0.00 | 0.00 | |
Assets Liabilities Change (Total) |
(149.10) | (108.10) | (128.80) | (153.70) | |
Investments Change (Net) |
1,431.80 | (815.60) | (230.40) | (236.10) | |
Issuance/Purchase of Shares |
125.30 | 49.20 | (38.30) | (365.60) |